Third Rock Ventures V, L.P. sold 18,572 shares of Rapport Therapeutics, Inc. at $40.05 for −$744k on May 26, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
10% owner
10%
Filed May 28, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$743,752.88Shares × reported price
Shares traded
18,572Common Stock
Price per share
$40.05Reported price. Read footnotes for ranges.
% of reported position traded
0.29%This security and ownership context
Holdings after
6,280,525Direct
Trade date
May 26, 2026Sell
Filed
May 28, 2026, 4:15 PM ET2-day reporting delay
Accession
0001193125-26-245259Code S · Transaction 386672
How reported position traded is calculated

Shares sold ÷ (holdings after + shares sold). Estimated position before: 6,299,097 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

RAPP price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
RAPP · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −7.4%1w ago −13%1d ago −4.5%
Returns since7d −5.1%30d +1.4%90d +33%180d1y

Footnotes in full

F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 21, 2025, previously adopted by the Reporting Person. F2: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2). F3: These shares are directly held by Third Rock Ventures V, L.P. ("TRV V"). The general partner of TRV V is Third Rock Ventures GP V, L.P. ("TRV GP V"). The general partner of TRV GP V is TRV GP V, LLC ("TRV GP V LLC"). Each of TRV GP V and TRV GP V LLC disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares. F4: The shares are held directly by Third Rock Ventures VI, L.P. ("TRV VI"). The general partner of TRV VI is Third Rock Ventures GP VI, L.P. ("TRV GP VI"). The general partner of TRV GP VI is TRV GP VI, LLC ("TRV GP VI LLC"). Each of TRV GP VI, and TRV GP VI LLC, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares. Each of Reporting Persons disclaims the existence of a Section 13(d) "group" as between any TRV V related parties and any TRV VI related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.